| General Information | |
|---|---|
| ZINC ID | ZINC000028898414 |
| Molecular Weight (Da) | 552 |
| SMILES | C[C@H](NS(=O)(=O)C(F)(F)F)c1ccc(S(=O)(=O)c2ccccc2S(=O)(=O)c2ccccc2F)cc1 |
| Molecular Formula | C21F4N1O6S3 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 120.758 |
| HBA | 6 |
| HBD | 1 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 35 |
| LogP | 5.672 |
| Activity (Ki) in nM | 25.1189 |
| Polar Surface Area (PSA) | 139.59 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | - |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.815 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.14 |
| Ilogp | 2.58 |
| Xlogp3 | 4.13 |
| Wlogp | 8.59 |
| Mlogp | 3.46 |
| Silicos-it log p | 2.92 |
| Consensus log p | 4.34 |
| Esol log s | -5.71 |
| Esol solubility (mg/ml) | 0.00107 |
| Esol solubility (mol/l) | 0.00000193 |
| Esol class | Moderately |
| Ali log s | -6.77 |
| Ali solubility (mg/ml) | 0.000094 |
| Ali solubility (mol/l) | 0.00000017 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.62 |
| Silicos-it solubility (mg/ml) | 0.00000132 |
| Silicos-it solubility (mol/l) | 2.40E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.73 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 2 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.78 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.076 |
| Logd | 2.852 |
| Logp | 4.527 |
| F (20%) | 0.002 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 98.18% |
| Vdss | 0.321 |
| Fu | 1.35% |
| Cyp1a2-inh | 0.128 |
| Cyp1a2-sub | 0.394 |
| Cyp2c19-inh | 0.545 |
| Cyp2c19-sub | 0.926 |
| Cl | 1.124 |
| T12 | 0.012 |
| H-ht | 0.962 |
| Dili | 0.999 |
| Roa | 0.066 |
| Fdamdd | 0.986 |
| Skinsen | 0.04 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.13 |
| Bcf | 0.222 |
| Igc50 | 3.156 |
| Lc50 | 3.78 |
| Lc50dm | 5.081 |
| Nr-ar | 0 |
| Nr-ar-lbd | 0.021 |
| Nr-ahr | 0.044 |
| Nr-aromatase | 0.067 |
| Nr-er | 0.276 |
| Nr-er-lbd | 0.029 |
| Nr-ppar-gamma | 0.007 |
| Sr-are | 0.54 |
| Sr-atad5 | 0.003 |
| Sr-hse | 0.003 |
| Sr-mmp | 0.745 |
| Sr-p53 | 0.002 |
| Vol | 465.91 |
| Dense | 1.183 |
| Flex | 0.333 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.444 |
| Synth | 3.031 |
| Fsp3 | 0.143 |
| Mce-18 | 56 |
| Natural product-likeness | -1.076 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |